Mumbai: The U.S. Food and Drug Administration has granted approval to four drugs manufactured by the Gujarat-based pharmaceutical Zydus Cadilla.

Announcing this Thursday, the company said authorities in the US had given the green signal to its fats-lowering agents and tentative approval to an anti-depressant, anti-hypertensive drug as well as a hormonal drug administered in the treatment of breast cancer.

The company said while anti-depressant Escitalopram Oxalate tablets had an annual sales turnover of $3 billion in 2007, the LDL cholesterol lowering drug Pravastain Sodium tablets, according to USFDA's National Drug Code directory (NDC), has $1.9 billion American market.

The company quoted NDC to say that the hormonal therapy drug Anastrazole has an estimated market of $13 million and the anti-hypertensive Losartan Potassium and Hydrochlorthiazide had approximate sales touching $785 million last year.